WO2003042661A3 - Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer - Google Patents

Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer Download PDF

Info

Publication number
WO2003042661A3
WO2003042661A3 PCT/US2002/036810 US0236810W WO03042661A3 WO 2003042661 A3 WO2003042661 A3 WO 2003042661A3 US 0236810 W US0236810 W US 0236810W WO 03042661 A3 WO03042661 A3 WO 03042661A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
cancer
diagnosis
compositions
modulators
Prior art date
Application number
PCT/US2002/036810
Other languages
English (en)
Other versions
WO2003042661A2 (fr
WO2003042661A8 (fr
Inventor
Daniel Afar
Natasha Aziz
Wendy M Ginsburg
Kurt C Gish
Richard Glynne
Peter A Hevezi
David H Mack
Richard Murray
Susan R Watson
Keith E Wilson
Albert Zlotnik
Original Assignee
Protein Design Labs Inc
Daniel Afar
Natasha Aziz
Wendy M Ginsburg
Kurt C Gish
Richard Glynne
Peter A Hevezi
David H Mack
Richard Murray
Susan R Watson
Keith E Wilson
Albert Zlotnik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc, Daniel Afar, Natasha Aziz, Wendy M Ginsburg, Kurt C Gish, Richard Glynne, Peter A Hevezi, David H Mack, Richard Murray, Susan R Watson, Keith E Wilson, Albert Zlotnik filed Critical Protein Design Labs Inc
Priority to AU2002357734A priority Critical patent/AU2002357734A1/en
Priority to JP2003544445A priority patent/JP2005525789A/ja
Priority to CA002467433A priority patent/CA2467433A1/fr
Priority to EP02792272A priority patent/EP1497454A2/fr
Publication of WO2003042661A2 publication Critical patent/WO2003042661A2/fr
Publication of WO2003042661A8 publication Critical patent/WO2003042661A8/fr
Publication of WO2003042661A3 publication Critical patent/WO2003042661A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

Cette invention concerne des gènes dont l'expression est régulée positivement ou négativement dans certains cancers ou pathologies spécifiques, ou bien dont l'expression est régulée dans les états pathologiques. Sont également décrites des méthodes et des compositions connexes convenant pour le diagnostic, le pronostic et le traitement de ces pathologie ainsi que ces méthodes permettant d'identifier les modulateurs de ces dernières.
PCT/US2002/036810 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer WO2003042661A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002357734A AU2002357734A1 (en) 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
JP2003544445A JP2005525789A (ja) 2001-11-13 2002-11-13 ガンの診断方法、ガンのモジュレータのスクリーニング組成物及び方法
CA002467433A CA2467433A1 (fr) 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
EP02792272A EP1497454A2 (fr) 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33246401P 2001-11-21 2001-11-21
US60/332,464 2001-11-21
US33439301P 2001-11-29 2001-11-29
US60/334,393 2001-11-29
US33539401P 2001-12-03 2001-12-03
US60/335,394 2001-12-03
US34037601P 2001-12-14 2001-12-14
US60/340,376 2001-12-14
US34721102P 2002-01-08 2002-01-08
US60/347,211 2002-01-08
US34734902P 2002-01-10 2002-01-10
US60/347,349 2002-01-10
US35525002P 2002-02-08 2002-02-08
US35525702P 2002-02-08 2002-02-08
US60/355,250 2002-02-08
US35671402P 2002-02-13 2002-02-13
US60/356,714 2002-02-13
US35907702P 2002-02-20 2002-02-20
US60/359,077 2002-02-20
US36880902P 2002-03-29 2002-03-29
US60/368,809 2002-03-29
US37011002P 2002-04-04 2002-04-04
US60/370,110 2002-04-04
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
US38661402P 2002-06-05 2002-06-05
US60/386,614 2002-06-05
US39683902P 2002-07-16 2002-07-16
US60/396,839 2002-07-16
US39777502P 2002-07-22 2002-07-22
US39784502P 2002-07-22 2002-07-22
US60/397,775 2002-07-22
US60/397,845 2002-07-22
US40945002P 2002-09-09 2002-09-09
US60/409,450 2002-09-09

Publications (3)

Publication Number Publication Date
WO2003042661A2 WO2003042661A2 (fr) 2003-05-22
WO2003042661A8 WO2003042661A8 (fr) 2003-10-16
WO2003042661A3 true WO2003042661A3 (fr) 2004-10-28

Family

ID=32097246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036810 WO2003042661A2 (fr) 2001-11-13 2002-11-13 Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer

Country Status (1)

Country Link
WO (1) WO2003042661A2 (fr)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090176722A9 (en) 2000-01-28 2009-07-09 Shiv Srivastava Androgen-regulated PMEPA1 gene and polypeptides
AU6986201A (en) 2000-06-16 2002-01-02 Biogen Inc Renal regulatory elements and methods of use thereof
US20060035237A1 (en) * 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
DE60224275T2 (de) 2001-06-01 2008-12-11 Biogen Idec Ma Inc., Cambridge Moleküle und verfahren zur inhibierung der freisetzung von kim-1
WO2003024392A2 (fr) * 2001-09-18 2003-03-27 Genentech, Inc. Compositions et procedes pour le diagnostic et le traitement des tumeurs
WO2003076571A2 (fr) * 2002-03-04 2003-09-18 Avalon Pharmaceuticals Genes lies au cancer utilises comme cibles en chimiotherapie
WO2003080856A2 (fr) * 2002-03-19 2003-10-02 Curagen Corporation Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees
JP2005530856A (ja) * 2002-06-21 2005-10-13 ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 膜関連腫瘍内皮マーカー
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
CA2492160A1 (fr) 2002-07-12 2004-01-22 The Johns Hopkins University Vaccins a la mesotheline et systemes de modele
EP1575993A4 (fr) * 2002-08-26 2007-07-25 Univ Case Western Reserve Methodes de traitement de patients et d'identification de therapeutique
AU2003268494A1 (en) * 2002-09-11 2004-04-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7521543B2 (en) * 2002-10-23 2009-04-21 Ludwig Institute For Cancer Research A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same
ES2311122T3 (es) 2002-12-30 2009-02-01 Biogen Idec Ma Inc. Antagonistas de kim-1 y uso para la modulacion del sistema inmune.
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
JP2006526986A (ja) * 2003-06-06 2006-11-30 アストラゼネカ・アクチエボラーグ 炎症性大腸炎の診断方法
EP1644406B1 (fr) 2003-07-11 2012-08-15 DeveloGen Aktiengesellschaft Utilisation de produits des proteines dg153 secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite et/ou du syndrome metabolique
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
EP1670350A4 (fr) 2003-10-07 2008-02-13 Millennium Pharm Inc Molecules d'acides nucleiques et proteines pour l'identification, l'evaluation, la prevention et le traitement du cancer de l'ovaire
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005054864A2 (fr) * 2003-11-22 2005-06-16 Bayer Healthcare Ag Diagnostic et traitements therapeutiques des maladies associees a l'element 1 de la sous-famille k du canal potassique (kcnk1)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP1584684A1 (fr) * 2004-02-20 2005-10-12 Samsung Electronics Co., Ltd. Protéine associée au cancer du sein, gène la codant et méthode de diagnostique du cancer du sein utilisant ladite protéine et ledit gène
JP2005314397A (ja) * 2004-03-31 2005-11-10 Mitsubishi Chemicals Corp 抗コンドロモジュリン−１特異的抗体及びその利用
US20080260742A1 (en) * 2004-04-09 2008-10-23 Takeda Pharmaceutical Company Limited Preventives/Remedies for Cancer
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US20080038255A1 (en) * 2004-06-04 2008-02-14 Aplied Research Systems Ars Holding N.V. Splice Variant of Unc5h2
US20060024677A1 (en) * 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1794314A2 (fr) * 2004-07-23 2007-06-13 Bayer HealthCare AG Agents diagnostiques et therapeutiques pour pathologies associees au recepteur 1 de peptide intestinal vasoactif (vpac1)
US20090214517A1 (en) * 2004-07-27 2009-08-27 Justin Wong Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
DE102004045705A1 (de) 2004-09-21 2006-04-06 B.R.A.H.M.S Ag Verwendungen der Carbamoylphosphat Synthetase 1(CPS) als humoraler Biomarker für die Diagnose von Tumorerkrankungen und chronisch entzündlichen Darmerkrankungen
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1791565B1 (fr) 2004-09-23 2016-04-20 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
WO2006053442A1 (fr) * 2004-11-22 2006-05-26 Diagnocure Inc. Cible specifique et sensible (calml3) pour un diagnostic, un pronostic et/ou une therapie adaptee au diagnostic et au savoir-faire du domaine, d'un cancer du poumon
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
WO2006090389A2 (fr) * 2005-02-24 2006-08-31 Compugen Ltd. Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes
PL2325306T3 (pl) 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1
DE602006016413D1 (de) 2005-03-02 2010-10-07 Biogen Idec Inc Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen
WO2006107259A1 (fr) * 2005-04-07 2006-10-12 Astrazeneca Ab Procede pour l’evaluation de la predisposition et/ou de la susceptibilite a la bpco au moyen de l’analyse de fgf-bp1
WO2006113671A2 (fr) * 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Marqueur de methylation pour le diagnostic et le traitement des cancers
SG183708A1 (en) * 2005-04-15 2012-09-27 Epigenomics Ag Methods and nucleic acids for analyses of cellular proliferative disorders
GB0508863D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Peptide
WO2006118308A1 (fr) 2005-05-02 2006-11-09 Toray Industries, Inc. Composition et procede permettant de diagnostiquer un cancer esophagien et une metastase d’un cancer esophagien
US7910552B2 (en) 2005-05-27 2011-03-22 Bbs-Bioactive Bone Substitutes Oy Bone morphogenetic proteins containing a heparin binding site and osteogenic devices and pharmaceutical products containing thereof
DK1957539T3 (da) 2005-12-08 2013-05-06 Medarex Inc Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse
ES2544957T3 (es) 2006-03-21 2015-09-07 Genentech, Inc. Terapia combinada que implica antagonistas alfa5beta1
WO2007115213A2 (fr) * 2006-03-30 2007-10-11 Epigenomics Ag Méthodes et acides nucléiques pour des analyses de troubles prolifératifs cellulaires
WO2007118704A2 (fr) * 2006-04-17 2007-10-25 Epigenomics Ag Procédés et acides nucléiques pour détecter des troubles de prolifération de cellules colorectales
US20100184027A1 (en) * 2006-07-13 2010-07-22 Epigenomics Ag Methods and nucleic acids for analyses of cellular proliferative disorders
EP1932854A1 (fr) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides s'apparentant à une protéine de membrane associée à un lysosome (LAMP), ligands correspondants et leur utilisation dans le cadre de la détection et de la purification de cellules dendritiques plasmacytoïdes humaines
WO2008104803A2 (fr) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Protéines
WO2008104805A2 (fr) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Protéines
AU2012244137B2 (en) * 2007-07-27 2015-06-11 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumours
JP6008461B2 (ja) * 2007-07-27 2016-10-19 イマティクス バイオテクノロジーズ ゲーエムベーハー 神経細胞性脳腫瘍に対する新規免疫療法
EP2565204B1 (fr) 2007-07-27 2015-10-07 immatics biotechnologies GmbH Nouveaux épitopes immunogènes pour l'immunothérapie
AU2008296927C1 (en) 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
SI2200700T1 (sl) 2007-09-26 2016-04-29 Genentech, Inc. Nova protitelesa
WO2009092806A2 (fr) 2008-01-25 2009-07-30 Aarhus Universitet Inhibition de l'exosite sélectif de l'activité de papp-a contre igfbp-4
EP2257301B1 (fr) 2008-03-03 2014-01-22 The University of Miami Immunothérapie à base de cellules cancéreuses allogéniques
EP2119726B2 (fr) * 2008-05-14 2017-11-29 Immatics Biotechnologies GmbH Nouveaux peptides puissants de classe II-MHC dérivés de la survivine et neurocane
JPWO2009142257A1 (ja) 2008-05-21 2011-09-29 東レ株式会社 食道ガン判定用組成物及び方法
NZ601647A (en) * 2008-05-30 2013-09-27 Curis Inc Variant hhip1 protein and methods and uses thereof
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US9290556B2 (en) 2008-09-29 2016-03-22 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
EP2448966B1 (fr) 2009-07-03 2018-11-14 Avipep Pty Ltd Immunoconjugués et leurs procédés de production
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
CA2784610C (fr) 2009-12-23 2020-07-14 Avipep Pty Ltd Immuno-conjugues et leurs methodes de production
KR101738203B1 (ko) 2010-04-15 2017-05-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
CA3220104A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugues modifies par la cysteine
PT2621526T (pt) 2010-09-29 2018-08-02 Seattle Genetics Inc Conjugados de anticorpo com fármaco (adc) que se ligam a proteínas 191pad12
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
WO2012142662A1 (fr) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Molécules à domaine variable modifié et procédés de préparation et d'utilisation de celles-ci
JP5987053B2 (ja) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
WO2013045464A1 (fr) * 2011-09-26 2013-04-04 Roche Diagnostics Gmbh Biomarqueurs d'adnc dans du sang total pour l'évaluation du cancer colorectal
EP2750713B1 (fr) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués associés
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2014034754A1 (fr) 2012-08-31 2014-03-06 塩野義製薬株式会社 Peptide dérivé de psf1
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
HUE042731T2 (hu) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
JP6307519B2 (ja) 2012-12-21 2018-04-04 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびその結合体
EA032986B1 (ru) 2012-12-21 2019-08-30 Медимьюн Лимитед Пирролобензодиазепины
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
PT3055331T (pt) 2013-10-11 2021-04-05 Oxford Bio Therapeutics Ltd Anticorpos conjugados contra ly75 para o tratamento de cancro
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3082875B1 (fr) 2013-12-16 2020-11-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (fr) 2014-09-12 2019-11-20 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
CA2957354A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Anticorps et conjugues modifies genetiquement avec de la cysteine
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
EP3226909A1 (fr) 2014-12-03 2017-10-11 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
EP3464280B1 (fr) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
JP6671555B2 (ja) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム ピロロベンゾジアゼピン抗体複合体
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2018253948A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
CN111788208B (zh) 2017-09-20 2023-11-24 Ph制药有限公司 泰兰他汀类似物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (ja) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
CN112083168A (zh) * 2019-06-14 2020-12-15 复旦大学附属华山医院 多肽段诊断模型及其在预测髓母细胞瘤转移风险中的应用
CN110819714B (zh) * 2019-11-22 2023-01-10 南方医科大学深圳医院 一种抑癌基因及其应用
CN114350640B (zh) * 2019-12-13 2023-09-08 中国科学院天津工业生物技术研究所 一株表达几丁质酶重组菌的构建及高酶活突变体的筛选
CN111748623B (zh) * 2020-06-08 2022-11-04 郑州大学第一附属医院 肝癌患者是否复发的预测标志物及试剂盒
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2023147329A1 (fr) 2022-01-26 2023-08-03 Genentech, Inc. Inducteurs chimiques conjugués à des anticorps de dégradation et procédés associés
WO2023147328A1 (fr) 2022-01-26 2023-08-03 Genentech, Inc. Inducteurs chimiques de dégradation conjugués à des anticorps avec lieurs maléimide hydolysables et méthodes associées
CN114966062B (zh) * 2022-07-29 2022-09-30 北京大学第三医院（北京大学第三临床医学院） 用于预测抗mda5抗体阳性皮肌炎合并间质性肺病的分子标记物及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM J.Y. ET AL: "Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1512, June 2001 (2001-06-01), pages 335 - 344, XP004245520 *
SATO H. ET AL: "Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins", J. BIOL. CHEM., vol. 274, no. 17, 23 April 1999 (1999-04-23), pages 11455 - 11458, XP002941607 *

Also Published As

Publication number Publication date
WO2003042661A2 (fr) 2003-05-22
WO2003042661A8 (fr) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2003042661A3 (fr) Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
WO2002059377A3 (fr) Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
WO2003025138A3 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
WO2004073657A3 (fr) Methode de diagnostic du cancer, composition et methodes de criblage destinees a identifier des modulateurs du cancer
WO2003003906A3 (fr) Procede de diagnostic du cancer de la vessie, compositions et procedes de criblage de modulateurs du cancer de la vessie
WO2002102235A3 (fr) Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
WO2004048938A3 (fr) Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
WO2004113571A3 (fr) Genes specifiques de la prostate et leur utilisation comme cibles dans le traitement et le diagnostic du cancer de la prostate
WO2002030268A3 (fr) Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
EP2258873A3 (fr) Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
WO2004063355A3 (fr) Nouveaux procedes de diagnostic d'un cancer metastatique, compositions et procedes de depister des modulateurs du cancer metastatique
WO2004065583A3 (fr) Marqueurs d'expression genique pour le pronostic du cancer du sein
WO2004008147A3 (fr) Diagnostic et prevention de l'invasion des cellules cancereuses
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
WO2007015947A3 (fr) Methodes et trousses pour la prediction du succes therapeutique, de la survie sans recidive et globale dans des therapies du cancer
WO2007006408A3 (fr) Methodes et kits de prevision et de surveillance d'une reponse directe a une therapie anti-cancereuse
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2006027693A3 (fr) Genes et arn variants specifiques de tumeur et leurs utilisations comme cibles pour le traitement et le diagnostic du cancer
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2005119260A3 (fr) Methodes de prediction et de surveillance de reponse au traitement du cancer
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
WO2003079982A3 (fr) Amplification de genes en cas de cancer
WO2004046332A3 (fr) Genes amplifies impliques dans un cancer
WO2001071357A3 (fr) Proteines, genes et leur utilisation pour diagnostiquer et traiter le cancer de la poitrine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

Free format text: IN PCT GAZETTE 21/2003 UNDER (30) REPLACE "NOT FURNISHED" BY "60/355,250"

WWE Wipo information: entry into national phase

Ref document number: 2002792272

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2467433

Country of ref document: CA

Ref document number: 2003544445

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002792272

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002792272

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)